Biotech Startups

Abolis is a microbial biotechnology company that designs custom microorganisms to produce ingredients sustainably using metabolic engineering, fermentation, and machine learning. The company serves cosmetics, healthcare, nutrition, and specialty chemicals industries with tailored biosolutions for manufacturing.

1 investor

Abologix is a biopharmaceutical company developing two monoclonal antibodies that target JAM-C and Olfactomedin-like protein 3 (Olfml3) for oncology indications. It is a spin-out from the University of Geneva and Geneva University Hospitals.

1 investor

Arx is a self-hosted microbial genomics platform that enables researchers to store, organize, and analyze genomic data through interactive visualization and comparative analysis tools. The platform serves academic and research institutions studying microbial genomes.

1 investor

ABSCINT develops non-invasive in vivo PET imaging diagnostics using single-domain antibodies (sdAbs) as radiolabeled targeting agents, including an anti-HER2 PET tracer for whole-body imaging. Its technology is aimed at physicians diagnosing and monitoring HER2-driven cancers such as breast cancer, supporting patient identification, disease assessment, and treatment monitoring.

1 investor

Absentia Labs develops AI foundation models that learn from biological, chemical, and clinical data to model drug behavior and predict safety and efficacy. Its systems are aimed at accelerating therapeutic development and reducing reliance on animal testing for the pharmaceutical and drug discovery industry.

1 investor

ABYRX develops synthetic, absorbable surgical biomaterials, including a bone hemostat used to stop bleeding on bone surfaces during surgery. Its products are tissue-free and designed to absorb after implantation for use in surgical and orthopedic procedures.

1 investor

Acadia is a biopharmaceutical company developing therapies for underserved neurological disorders and rare diseases. The company operates across North America and Europe, leveraging expertise in areas including Parkinson's disease psychosis and Rett syndrome.

1 investor

Accelerated Biosciences commercializes human trophoblast stem cells (hTSC) and derived platforms for therapeutic development, serving pharmaceutical and biotech partners seeking accelerated pathways to clinical products. The company addresses aging and healthcare cost challenges through cell-based therapeutics.

1 investor

Accelerated Diagnostics is developing decentralised diagnostics for human and veterinary markets, with a product launch planned for July 2026.

1 investor

Access Bio develops in vitro diagnostics technology, producing rapid diagnostic tests, molecular tests, analyzers, and COVID-19 tests (including PCR, serology, and antigen testing) to detect malaria and other diseases. It serves international public health agencies and organizations.

1 investor

Access2Bone develops bone graft products containing human tissue-based compositions for orthopedic surgeries. The company's offerings are designed for foot, ankle, and spine fusion procedures.

1 investor

Accession Therapeutics develops cancer treatments by harnessing immune system mechanisms, with a focus on T cell receptor therapies and engineered cell therapies. The company is led by experienced biotech entrepreneurs and scientific experts with a track record in bringing immunological oncology projects to clinical development.

1 investor

ACEA Therapeutics is a clinical-stage pharmaceutical company developing small molecule inhibitors, antibody drug conjugates, and cell therapies to address unmet needs in cancer, autoimmune disease, and COVID-19. The company operates manufacturing and commercial capabilities in China and has multiple candidates in clinical development.

1 investor

AcelRx develops medical pain-management products, including a sublingual sufentanil delivery device for use in hospital settings as an alternative to IV patient-controlled analgesia. The company focuses on pharmaceutical and drug-delivery technology for acute pain management.

1 investor

Acepodia develops cell therapies for cancer treatment, leveraging proprietary immune cell engineering and tumor-targeting technology to create off-the-shelf therapeutic options for broad patient populations.

1 investor

Achilles Therapeutics, a UK biotech company, is in members voluntary (solvent) liquidation as of March 2025, with joint liquidators appointed from Teneo Financial Advisory. The page is a liquidation notice for creditors and shareholders rather than an active company site.

1 investor

Aclipse Therapeutics is a clinical-stage biopharmaceutical company developing disease-modifying drug candidates for life-threatening neuromuscular and severe diseases, using genomic, proteomic, and biomarker data. Its lead programs include M107 for gastroparesis and M102 for amyotrophic lateral sclerosis (ALS).

1 investor

ACM Biolabs develops a patent-protected polymer/lipid hybrid, non-viral drug delivery technology (ATP) that carries payloads such as oligonucleotides, small molecules, proteins, and mRNA to improve their efficacy. The company applies this platform to programs including a thermostable mRNA rabies vaccine and oncology immunotherapies targeting immunologically cold tumors.

1 investor

Acorn Genetics is developing technology to detect genetic and epigenetic markers rapidly and on-site, without sending samples to central labs. Its applications span disease marker detection and genomic monitoring for crop protection, ecosystems, and food security.

1 investor

Acrobat Genomics operates a closed-loop platform combining AI with laboratory experimentation to engineer proteins such as compact RNA-guided nucleases, with each cycle producing proprietary data to improve the next. The company applies its platform to develop genetic medicines for rare diseases and runs research programs in areas including neurodegeneration and interstitial lung disease.

1 investor

Biotech developing small-molecule therapies for respiratory, inflammatory and autoimmune diseases, acquired by Boehringer Ingelheim.

1 investor

Activ'Inside develops proprietary food supplement active ingredients for neuronutrition and nutricosmetics applications, supported by scientific research and clinical studies. The company supplies branded ingredients and botanical extracts to manufacturers formulating nutraceutical products.

1 investor

Vectura provides inhaled and nasal drug development services, combining formulation science, device technology and development expertise for small molecules, biologics, complex combinations and generic products across pMDI, DPI, nasal inhaler and nebulization devices. It works with pharmaceutical partners and licensees, having contributed to 13 launched inhaled medicines, and following a 2025 acquisition operates within Phillips Medisize.

1 investor

ActNova develops "ActVerse", a web-based software that analyzes videos of animal experiments to automatically and accurately assess animal behavior. It targets pharmaceutical companies, hospitals, and university research labs conducting preclinical animal testing, aiming to reduce the number of animals sacrificed in research.

1 investor